Between desire and rape - narratives about being intimate partners and becoming pregnant in a violent relationship.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 3855602)

Published in Glob Health Action on December 05, 2013

Authors

Kerstin Edin1, Bo Nilsson

Author Affiliations

1: Epidemiology and Global Health, Umeå University, Umeå, Sweden; Department of Nursing, Umeå University, Umeå, Sweden; Umeå Centre of Gender Studies, Umeå University, Umeå, Sweden; kerstin.edin@nurs.umu.se.

Articles cited by this

Violence against women: an integrated, ecological framework. Violence Against Women (1998) 4.76

Risk factors for domestic violence: findings from a South African cross-sectional study. Soc Sci Med (2002) 3.90

Women exposed to intimate partner violence: expectations and experiences when they encounter health care professionals: a meta-analysis of qualitative studies. Arch Intern Med (2006) 3.23

A global overview of gender-based violence. Int J Gynaecol Obstet (2002) 3.04

Intention to become pregnant and low birth weight and preterm birth: a systematic review. Matern Child Health J (2011) 2.32

Intimate partner sexual assault against women: frequency, health consequences, and treatment outcomes. Obstet Gynecol (2005) 1.81

Pregnancy and domestic violence: a review of the literature. Trauma Violence Abuse (2004) 1.76

The dark consequences of marital rape. Am J Nurs (1989) 1.61

Is intimate partner violence associated with unintended pregnancy? A review of the literature. Trauma Violence Abuse (2005) 1.57

The relationship between pregnancy intendedness and physical violence in mothers of newborns. The PRAMS Working Group. Obstet Gynecol (1995) 1.42

Community level effects of gender inequality on intimate partner violence and unintended pregnancy in Colombia: testing the feminist perspective. Soc Sci Med (2004) 1.42

Forced sexual initiation, sexual intimate partner violence and HIV risk in women: a global review of the literature. AIDS Behav (2013) 1.34

Reproductive coercion: connecting the dots between partner violence and unintended pregnancy. Contraception (2010) 1.31

Power and violence: the relation between communication patterns, power discrepancies, and domestic violence. J Consult Clin Psychol (1993) 1.27

Asking about intimate partner violence: advice from female survivors to health care providers. Patient Educ Couns (2005) 1.25

Pregnancy intendedness and physical abuse around the time of pregnancy: findings from the pregnancy risk assessment monitoring system, 1996-1997. PRAMS Working Group. Pregnancy Risk Assessment Monitoring System. Matern Child Health J (2000) 1.21

What happens when health care providers ask about intimate partner violence? A description of consequences from the perspectives of female survivors. J Am Med Womens Assoc (2003) 1.19

Recovered memories of abuse in women with documented child sexual victimization histories. J Trauma Stress (1995) 1.17

Interactions between victims of intimate partner violence against women and the health care system: policy and practice implications. Trauma Violence Abuse (2007) 1.15

Reproductive health consequences of intimate partner violence. A nursing research review. Clin Nurs Res (2000) 1.08

Controlling behavior, power relations within intimate relationships and intimate partner physical and sexual violence against women in Nigeria. BMC Public Health (2011) 1.06

A qualitative exploration of the nature of domestic violence in pregnancy. Violence Against Women (2006) 1.04

"Keeping up a front": narratives about intimate partner violence, pregnancy, and antenatal care. Violence Against Women (2010) 1.03

Why physicians and nurses ask (or don't) about partner violence: a qualitative analysis. BMC Public Health (2012) 1.03

Differing effects of partner and nonpartner sexual assault on women's mental health. Violence Against Women (2007) 0.99

Prevalence of physical and sexual abuse before and during pregnancy among Swedish couples. Acta Obstet Gynecol Scand (1999) 0.98

Violence against pregnant women will remain hidden as long as no direct questions are asked. Midwifery (2002) 0.97

Moving beyond disclosure: women's perspectives on barriers and motivators to seeking assistance for intimate partner violence. Women Health (2004) 0.96

The impact of gender role ideology, male expectancies, and acculturation on wife abuse. Int J Law Psychiatry (2003) 0.96

Choice and empowerment for battered women who stay: toward a constructivist model. Soc Work (2000) 0.96

An integrative review of separation in the context of victimization: consequences and implications for women. Trauma Violence Abuse (2004) 0.93

Self-structure and self-esteem stability: the hidden vulnerability of compartmentalization. Pers Soc Psychol Bull (2007) 0.93

Abuse experiences, perceptions, and associated decisions during the childbearing cycle. West J Nurs Res (2005) 0.90

The wavering line in the sand: the effects of domestic violence and sexual coercion. Issues Ment Health Nurs (2003) 0.90

Compartmentalization and integration: the evaluative organization of contextualized selves. J Pers (2007) 0.88

Surviving wife rape: how women define and cope with the violence. Violence Against Women (1995) 0.87

Debunking myths about trauma and memory. Can J Psychiatry (2005) 0.85

Marital rape: history, research, and practice. Trauma Violence Abuse (2003) 0.85

Screening for intimate partner violence: the impact of screener and screening environment on victim comfort. J Interpers Violence (2007) 0.85

The NSW Health routine screening for domestic violence program. N S W Public Health Bull (2007) 0.82

Love and violence: gender paradoxes in volatile attachments. Fam Process (1990) 0.79

Organization of parent knowledge: compartmentalization and integration in adult child-parent relationships. Pers Soc Psychol Bull (2010) 0.78

Screening for domestic violence in an antenatal clinic. Aust J Midwifery (2002) 0.78

Depressive and posttraumatic symptoms among women seeking protection orders against intimate partners: relations to coping strategies and perceived responses to abuse disclosure. Violence Against Women (2012) 0.77

Articles by these authors

(truncated to the top 100)

Structures of complement component C3 provide insights into the function and evolution of immunity. Nature (2005) 4.01

Complement and coagulation: strangers or partners in crime? Trends Immunol (2007) 2.48

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol (2011) 2.32

Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 2.12

Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes (2005) 1.96

[A nationwide study in primary health care: One out of four patients suffers from anxiety and depression]. Lakartidningen (2003) 1.96

Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res (2007) 1.66

Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol (2003) 1.53

Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes (2002) 1.52

Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol (2004) 1.51

Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol (2005) 1.45

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood (2006) 1.43

Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf) (2008) 1.41

Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells (2012) 1.36

An international serum standard for application in assays to detect human complement activation products. Mol Immunol (2013) 1.34

Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem Biophys Res Commun (2003) 1.33

Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Ophthalmology (2005) 1.32

Formation of composite endothelial cell-mesenchymal stem cell islets: a novel approach to promote islet revascularization. Diabetes (2008) 1.26

Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials (2005) 1.25

Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes (2007) 1.24

Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. J Clin Oncol (2008) 1.23

Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells (2014) 1.21

Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. J Biomed Mater Res A (2003) 1.19

The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol (2007) 1.14

C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J Immunol (2002) 1.13

Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation. Xenotransplantation (2008) 1.12

Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation (2010) 1.10

Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys (2004) 1.10

Impact of vaginal surgery on sexuality and quality of life in women with urinary incontinence or genital descensus. Acta Obstet Gynecol Scand (2005) 1.09

Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci (2002) 1.08

Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest (2015) 1.08

Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation (2007) 1.05

Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces. Biomaterials (2009) 1.03

Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv Drug Deliv Rev (2011) 1.01

Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation (2004) 1.01

Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer (2003) 1.01

Risk perception after genetic counseling in patients with increased risk of cancer. Hered Cancer Clin Pract (2009) 1.00

Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol (2005) 1.00

Acute antibody-mediated complement activation mediates lysis of pancreatic islets cells and may cause tissue loss in clinical islet transplantation. Transplantation (2008) 1.00

The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation. Transplantation (2011) 0.99

Intra- and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer. Virchows Arch (2009) 0.99

Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS (2008) 0.99

Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS One (2011) 0.99

Complement analysis in the 21st century. Mol Immunol (2007) 0.98

Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol (2010) 0.98

The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol (2002) 0.97

Composite islet-endothelial cell grafts: a novel approach to counteract innate immunity in islet transplantation. Am J Transplant (2005) 0.96

Quartz crystal microbalance-with dissipation monitoring (QCM-D) for real time measurements of blood coagulation density and immune complement activation on artificial surfaces. Biosens Bioelectron (2004) 0.96

Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J Immunol (2011) 0.96

Properdin in complement activation and tissue injury. Mol Immunol (2013) 0.95

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother (2008) 0.94

Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol (2008) 0.94

Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation (2003) 0.93

Preparatory studies of composite mesenchymal stem cell islets for application in intraportal islet transplantation. Ups J Med Sci (2010) 0.93

The role of whole blood in thrombin generation in contact with various titanium surfaces. Biomaterials (2006) 0.93

ABH blood group antigens in O-glycans of human glycophorin A. Arch Biochem Biophys (2004) 0.92

Platelets, complement, and contact activation: partners in inflammation and thrombosis. Adv Exp Med Biol (2012) 0.92

Uveal melanoma: a study on incidence of additional cancers in the Swedish population. Invest Ophthalmol Vis Sci (2006) 0.92

Evaluation of the blood compatibility of materials, cells, and tissues: basic concepts, test models, and practical guidelines. Adv Exp Med Biol (2013) 0.90

Regulated Extracellular Choline Acetyltransferase Activity- The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway. PLoS One (2013) 0.90

Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica (2003) 0.90

Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res (2004) 0.90

Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Eur J Haematol (2009) 0.89

Immune complex-mediated cytokine production is regulated by classical complement activation both in vivo and in vitro. Adv Exp Med Biol (2008) 0.89

Intraportal pig islet xenotransplantation into athymic mice as an in vivo model for the study of the instant blood-mediated inflammatory reaction. Xenotransplantation (2004) 0.89

Activated human platelets induce factor XIIa-mediated contact activation. Biochem Biophys Res Commun (2009) 0.89

Thrombotic disease in systemic lupus erythematosus is associated with a maintained systemic platelet activation. Br J Haematol (2004) 0.88

Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int (2011) 0.88

Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines (2005) 0.88

Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. Cancer Immunol Immunother (2008) 0.88

Vitacyte collagenase HA: a novel enzyme blend for efficient human islet isolation. Transplantation (2009) 0.87

Cryoglobulin-induced cytokine production via FcgammaRIIa: inverse effects of complement blockade on the production of TNF-alpha and IL-10. Implications for the growth of malignant B-cell clones. Br J Haematol (2005) 0.87

Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci (2003) 0.86

Surface-attached PEO in the form of activated Pluronic with immobilized factor H reduces both coagulation and complement activation in a whole-blood model. J Biomed Mater Res A (2006) 0.86

Improving islet transplantation: a road map for a widespread application for the cure of persons with type I diabetes. Curr Opin Organ Transplant (2009) 0.85

Inhibition of complement activation on a model biomaterial surface by streptococcal M protein-derived peptides. Biomaterials (2009) 0.85

Attenuation of cross-talk between the complement and coagulation cascades by C5a blockade improves early outcomes after intraportal islet transplantation. Transplantation (2010) 0.85

Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol Cancer Res (2009) 0.85

Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. PLoS One (2010) 0.84

Blood protein-polymer adsorption: implications for understanding complement-mediated hemoincompatibility. J Biomed Mater Res A (2011) 0.84

Identification of complement C3 as an autoantigen in inflammatory bowel disease. Eur J Gastroenterol Hepatol (2010) 0.84

Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack. Prostate (2005) 0.84

Microencapsulation of cells, including islets, within stable ultra-thin membranes of maleimide-conjugated PEG-lipid with multifunctional crosslinkers. Biomaterials (2013) 0.84

Anchoring of vascular endothelial growth factor to surface-immobilized heparin on pancreatic islets: implications for stimulating islet angiogenesis. Tissue Eng Part A (2010) 0.84

Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement-mediated hemolysis. Am J Reprod Immunol (2002) 0.84

Low molecular weight dextran sulfate as complement inhibitor and cytoprotectant in solid organ and islet transplantation. Mol Immunol (2008) 0.83

Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials (2012) 0.83

Prognostic factors in surgical stage I endometrial carcinoma. Acta Oncol (2004) 0.83

Desensitization with antigen-specific immunoadsorption interferes with complement in ABO-incompatible kidney transplantation. Transplantation (2012) 0.83

Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Res (2006) 0.83

Reproductive health in lesbian and bisexual women in Sweden. Acta Obstet Gynecol Scand (2010) 0.83

Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit Care (2002) 0.83

Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. Neurobiol Aging (2013) 0.82

Low molecular weight dextran sulfate is well tolerated in humans and increases endogenous expression of islet protective hepatocyte growth factor. Transplantation (2008) 0.82

Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens. Virchows Arch (2004) 0.82

The creation of an antithrombotic surface by apyrase immobilization. Biomaterials (2010) 0.82

Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects. J Immunol (2009) 0.81

Material-specific thrombin generation following contact between metal surfaces and whole blood. Biomaterials (2005) 0.81

Interobserver reproducibility of percent Gleason grade 4/5 in prostate biopsies. J Urol (2004) 0.81

Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma. Semin Thromb Hemost (2007) 0.81